MedTrace Logo

A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients

NCT01793844 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 732

Last updated 2015-12-11

No results posted yet for this study

Summary

This is a prospective , open, multicenter, randomized phase Ⅲ study. The investigators planed to include 732 untreated CD20 positive diffused large B cell lymphoma adults,to random to R-CHOP21, CHOP14 , R-CHOP14 regimen groups after signature the informed consents. The patients will receive safety assessment every cycles, and efficacy evaluation every 2 cycles. Every-two-months follow up will be received after finishing the treatment.

Conditions

  • Diffuse Large B-cell Lymphoma

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Lin TongYu · Sun Yat-sen University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2017-06-30
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01793844 on ClinicalTrials.gov